Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$1.22 - $2.03 $37,389 - $62,213
-30,647 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$1.27 - $2.23 $102,175 - $179,410
-80,453 Reduced 72.41%
30,647 $42,000
Q3 2021

Nov 15, 2021

BUY
$2.12 - $2.76 $235,532 - $306,636
111,100 New
111,100 $241,000

Others Institutions Holding OTLK

About Outlook Therapeutics, Inc.


  • Ticker OTLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 226,144,992
  • Market Cap $1.21B
  • Description
  • Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...
More about OTLK
Track This Portfolio

Track Susquehanna Fundamental Investments, LLC Portfolio

Follow Susquehanna Fundamental Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.